NCT01943422View on ClinicalTrials.gov

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2016

Study Completion Date

December 31, 2016

Conditions
Melanoma
Interventions
DRUG

High-dose Interferon alfa-2b

•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.

DRUG

Vemurafenib

"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."

Trial Locations (1)

15232

Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

John Kirkwood

OTHER

NCT01943422 - Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | Biotech Hunter | Biotech Hunter